MAPT and Alzheimer disease: Orexin itself has also been tied to AD pathology as increased cerebrospinal fluid (CSF) orexin levels are positively correlated to sleep deterioration and CSF tau protein levels in drug‐naïve AD patients (Liguori et al. 2014).